CSL Plasma Inc. v. United States Customs and Border Protection

33 F.4th 584
CourtCourt of Appeals for the D.C. Circuit
DecidedMay 10, 2022
Docket21-5282
StatusPublished
Cited by8 cases

This text of 33 F.4th 584 (CSL Plasma Inc. v. United States Customs and Border Protection) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
CSL Plasma Inc. v. United States Customs and Border Protection, 33 F.4th 584 (D.C. Cir. 2022).

Opinion

United States Court of Appeals FOR THE DISTRICT OF COLUMBIA CIRCUIT

Argued April 1, 2022 Decided May 10, 2022

No. 21-5282

CSL PLASMA INC., ET AL., APPELLANTS

v.

U.S. CUSTOMS AND BORDER PROTECTION AND CHRIS MAGNUS, COMMISSIONER, U.S. CUSTOMS AND BORDER PROTECTION, APPELLEES

Appeal from the United States District Court for the District of Columbia (No. 1:21-cv-02360)

Baruch Weiss argued the cause for appellants. With him on the briefs were R. Stanton Jones, Stephen K. Wirth, and John Swanson.

Lewis S. Yelin, Attorney, U.S. Department of Justice, argued the cause for appellees. With him on the brief were Brian M. Boynton, Principal Deputy Assistant Attorney General, and H. Thomas Byron III, Attorney.

Before: ROGERS and RAO, Circuit Judges, and GINSBURG, Senior Circuit Judge. 2 Opinion for the Court filed by Circuit Judge RAO.

RAO, Circuit Judge: In June 2021, U.S. Customs and Border Protection (“CBP”) announced that aliens seeking to sell blood plasma could no longer enter the United States using “B‑1” business visitor visas. Before this policy went into effect, a significant amount of the plasma used for medical treatments and research in this country came from Mexican nationals selling their plasma on the U.S. side of the southern border. CSL Plasma Inc., as well as other companies (“plasma companies”), had invested substantial resources to develop plasma collection facilities near the border to take advantage of this market.

The plasma companies sued, alleging that CBP’s policy runs afoul of the Administrative Procedure Act (“APA”) and unlawfully cuts off a major source of plasma that they use to manufacture therapies to treat a range of diseases. The district court concluded the plasma companies were not within the “zone of interests” of the B-1 business visitor classification set out in the Immigration and Nationality Act (“INA”) and sua sponte dismissed the suit for lack of subject matter jurisdiction.

We reverse. Whether the plasma companies are within the statutory zone of interests is a merits issue, not a jurisdictional one. See Lexmark Int’l, Inc. v. Static Control Components, Inc., 572 U.S. 118, 128 n.4 (2014). Moreover, the plasma companies’ claims easily fit within the zone of interests of the B‑1 classification, and therefore they have a cause of action under the APA.

I.

CSL Plasma and the other plaintiffs “collect[] human blood plasma from individual donors for use in the development and manufacturing” of medical therapies. 3 According to their complaint,1 the plasma companies have long depended on donations by “many thousands” of paid Mexican donors, who contribute a substantial portion of the plasma collected by the companies and whose donations make up some five to ten percent of all plasma collected nationwide. Until June of last year, Mexican donors would enter the United States and sell plasma at dozens of border area facilities in exchange for roughly $50 per donation. They typically entered the country using “border crossing cards,” a combined B‑1/B-2 (business and pleasure) visa that permits an alien to enter the United States for multiple limited stays.2 See 22 C.F.R. § 41.32; 8 C.F.R. § 212.1(c)(1)(i).

For decades, CBP and its predecessor agencies allowed Mexicans with border crossing cards to enter the United States to sell plasma. Even at the peak of the COVID-19 pandemic, when B‑1 visa holders were generally prohibited from entering the United States, the Department of Homeland Security “designated plasma donors as ‘essential’ and plasma collection a ‘critical infrastructure industry.’” That changed in June 2021, when CBP instructed its border agents not to allow aliens to enter with B‑1 visas if they were planning to sell plasma.3 To

1 The district court dismissed the case on zone of interests grounds, which, as explained below, go to whether plaintiffs had a cause of action. We assume the truth of a complaint’s well-pled factual allegations when we review dismissals for failure to state a claim. See Ashcroft v. Iqbal, 556 U.S. 662, 679 (2009). 2 The term “B‑1” comes from the regulations describing categories of nonimmigrants by reference to the relevant INA provisions. See 22 C.F.R. § 41.12 (citing Immigration and Nationality Act, Pub. L. No. 82-414, § 101(a)(15)(B), 66 Stat. 163, 167 (1952) (codified at 8 U.S.C. § 1101(a)(15)(B))). 3 The parties dispute the nature of CBP’s decision. The plasma companies allege that CBP announced a substantive change in policy 4 justify this plasma policy, as we will call it, CBP explained in a memorandum that “selling plasma constitutes labor for hire in violation of B‑1 nonimmigrant status, as both the labor (the taking of the plasma) and accrual of profits would occur in the U.S., with no principal place of business in the foreign country.” CBP said paid plasma donors were not proper B‑1 visitors because that category excludes anyone coming to engage in “labor” within the meaning of the INA’s B-1 classification.4

After learning of CBP’s plasma policy and failing to secure a political solution, the plasma companies filed suit and sought a preliminary injunction ordering CBP not to implement the policy and to allow plasma donors to enter with B‑1 visas. The plasma companies maintained that selling plasma is a legitimate B‑1 business visitor activity and that they have relied on CBP’s prior longstanding practice of allowing B‑1 visa holders to enter the United States to sell plasma. The companies alleged multiple violations of the APA, claiming CBP had adopted an erroneous interpretation of the INA’s B‑1 business classification; changed its longstanding policy in an

through a press release, while CBP maintains that it clarified its established interpretation of the B‑1 business visitor definition in an internal guidance document. We need not resolve this dispute for the purpose of this appeal, as it does not bear on the zone of interests analysis. 4 The INA’s B‑1 business visitor classification extends to an alien (other than one coming for the purpose of … performing skilled or unskilled labor …) having a residence in a foreign country which he has no intention of abandoning and who is visiting the United States temporarily for business. 8 U.S.C. § 1101(a)(15)(B). 5 arbitrary and capricious way by failing to consider the plasma companies’ reliance interests and the policy’s public health effects; and implemented the policy change through an unofficial memorandum even though it was a legislative rule that required notice and comment.

After the parties briefed the preliminary injunction motion, the district court sua sponte dismissed the complaint “for lack of standing.” CSL Plasma Inc. v. U.S. Customs & Border Prot., 2021 WL 5869149, at *1 (D.D.C. Dec. 3, 2021). The court explained that the APA’s “zone of interests” requirement was a matter of prudential standing and jurisdictional. Id. at *3. The plasma companies’ interests were not within the zone of interests protected by the B‑1 classification because the “B‑1/B-2 program … has always been intended to limit the influx of foreign workers to protect American labor.” Id. at *4 (cleaned up).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
33 F.4th 584, Counsel Stack Legal Research, https://law.counselstack.com/opinion/csl-plasma-inc-v-united-states-customs-and-border-protection-cadc-2022.